Mark Stenhouse
2021 - Prometheus Biosciences
In 2021, Mark Stenhouse earned a total compensation of $3.5M as Chief Operating Officer at Prometheus Biosciences.
Compensation breakdown
| Bonus | $25,000 |
|---|---|
| Non-Equity Incentive Plan | $212,500 |
| Option Awards | $2,909,459 |
| Salary | $359,615 |
| Other | $10,674 |
| Total | $3,512,248 |
Stenhouse received $2.9M in option awards, accounting for 83% of the total pay in 2021.
Stenhouse also received $25K in bonus, $212.5K in non-equity incentive plan, $359.6K in salary and $10.7K in other compensation.
Rankings
In 2021, Mark Stenhouse's compensation ranked 3,814th out of 12,415 executives tracked by ExecPay. In other words, Stenhouse earned more than 69.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,814 out of 12,415 | 69th |
Division Manufacturing | 1,559 out of 5,505 | 72nd |
Major group Chemicals And Allied Products | 633 out of 2,375 | 73rd |
Industry group Drugs | 562 out of 2,096 | 73rd |
Industry Pharmaceutical Preparations | 392 out of 1,546 | 75th |
Source: SEC filing on April 1, 2022.
Stenhouse's colleagues
We found three more compensation records of executives who worked with Mark Stenhouse at Prometheus Biosciences in 2021.